Averna Therapeutics
Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA
Company Overview
Snapshot
Founded in January 2022, Averna Therapeutics operates with 51–200 employees. The company has raised $82 million across one funding round from 10 investors, with Delos Capital and Novartis Venture Fund leading the Series A financing in June 2024.
Business overview
Averna Therapeutics is a biotechnology company focused on developing genomic medicines for a range of diseases, including genetic disorders, cancer, and autoimmune conditions. The company's core technology involves inserting therapeutic genetic instructions into specific "safe harbor" regions of the genome to ensure stable gene integration without disrupting cellular functions. Utilizing validated, non-viral delivery platforms, Averna aims to provide safe, efficient, scalable, and cost-effective treatments that allow for redosing to achieve curative outcomes within the Pharma & Medical Biotechnology and Drugs Discovery & Development sectors.
Strategic signal
In June 2024, Averna Therapeutics, operating under the name Exsilio Therapeutics, launched with an $82 million Series A financing round. This significant capital injection signals strong investor confidence in the company's innovative approach to developing redosable genomic medicines, positioning it to advance its pipeline and potentially disrupt the treatment landscape for various diseases.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent funding event for Averna Therapeutics?
- In June 2024, Averna Therapeutics launched with an $82 million Series A financing round, led by.
- What is Averna Therapeutics' primary focus?
- Averna Therapeutics specializes in developing genomic medicines that insert therapeutic genes into safe harbor regions within the DNA to treat genetic disorders, cancer, and autoimmune conditions.
- Which investors participated in Averna Therapeutics' Series A funding round?
- The Series A funding round for Averna Therapeutics included investments from.
- What is the strategic significance of Tal Zaks' involvement with Averna Therapeutics?
- In January 2025, former Moderna CMO Tal Zaks discussed Averna Therapeutics' work on gene editing for rare genetic diseases, underscoring the company's ambition to develop groundbreaking drugs and its potential impact on the biotechnology landscape.